Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Sanguine Biosciences1 site in 1 country200 target enrollmentFebruary 19, 2022

ConditionsNon Small Cell Lung Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Non Small Cell Lung Cancer
Sponsor: Sanguine Biosciences
Enrollment: 200
Locations: 1
Primary Endpoint: Biospecimen & Clinical Data Collection
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Registry

clinicaltrials.gov

Start Date

February 19, 2022

End Date

March 31, 2024

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Sanguine Biosciences

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participants willing and able to provide written informed consent
•Participants are willing and able to provide appropriate photo identification
•Participant's age 18 - 100 years old
•Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)
•Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records

Exclusion Criteria

•Participants who are pregnant or nursing
•Participants with a known history of HIV, hepatitis, or other infectious diseases
•Participants who have taken an investigational product in the last 30 days
•Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months
•Participants currently enrolled in a clinical trial
•Participants currently in remission

Outcomes

Primary Outcomes

Biospecimen & Clinical Data Collection

Time Frame: 10 years

The primary objective is to collect 2000 whole blood samples from subjects who are diagnosed with active lung cancer. The purpose of this study is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with various active lung cancers so that investigations can analyze how the immune response can take place, and aid in understanding active lung cancer biomarkers for future early diagnosis and treatment options.